AETERNA ZENTARIS ANNOUNCES ABSTRACT OF RESULTS FROM FIRST PEDIATRIC STUDY OF MACIMORELIN ACCEPTED FOR PRESENTATION AT THE 22N...
July 30 2020 - 7:35AM
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ( the “Company”),
a specialty biopharmaceutical company commercializing and
developing therapeutics and diagnostic tests, today announced that
the abstract on study results of its first pediatric study on
macimorelin has been selected for presentation at the 22nd European
Congress of Endocrinology (e-ECE 2020) being held September 5-9,
2020.
The accepted abstract titled Pharmacokinetics
and pharmacodynamics of macimorelin acetate (AEZS-130) in
paediatric patients with suspected growth hormone deficiency (GHD),
will be presented as an ePoster accommodated by an audio commentary
during the event.
Abstracts are under embargo until published in
Endocrine Abstracts before the start of e-ECE 2020. Endocrine
Abstracts is an entirely online, open-access and fully citable
collection of all the abstracts from e-ECE 2020. Once the abstract
is made public, it will be available on the Company’s website.
About e-ECE 2020
The European Congress of Endocrinology is the
European Society of Endocrinology’s premier event, attracting over
3,500 international delegates each year across the spectrum of
endocrinology. The event is a showcase of the best of science and
clinical practice across the fields of endocrinology and
metabolism, and aims to deliver to all audiences interested in the
field, whether you are an experienced consultant, a scientist or a
nurse, and whether you are well advanced in your career or just
starting out. e-ECE 2020 is this year’s fully digital Congress
bringing you the latest innovations in endocrine research and
patient care. For more information, please visit the event
website.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty
biopharmaceutical company commercializing and developing
therapeutics and diagnostic tests. The Company’s lead product,
Macrilen™ (macimorelin), is the first and only U.S. FDA and
European Commission approved oral test indicated for the diagnosis
of adult growth hormone deficiency (AGHD). Macrilen™ is currently
marketed in the United States through a license agreement with Novo
Nordisk and Aeterna Zentaris receives double-digit royalties on
sales. Aeterna Zentaris owns all rights to macimorelin outside of
the U.S. and Canada.
Aeterna Zentaris is also leveraging the clinical
success and compelling safety profile of macimorelin to develop it
for the diagnosis of child-onset growth hormone deficiency (CGHD),
an area of significant unmet need.
The Company is actively pursuing business
development opportunities for the commercialization of macimorelin
in Europe and the rest of the world, in addition to other
non-strategic assets to monetize their value. For more information,
please visit www.zentaris.com and connect with the Company on
Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains forward-looking
statements (as defined by applicable securities legislation) made
pursuant to the safe-harbor provision of the U.S. Securities
Litigation Reform Act of 1995, which reflect our current
expectations regarding future events. Forward-looking statements
may include, but are not limited to statements preceded by,
followed by, or that include the words "will," "expects,"
"believes," "intends," "would," "could," "may," "anticipates," and
similar terms that relate to future events, performance, or our
results. Forward-looking statements involve known and unknown risks
and uncertainties, including those discussed in our Annual Report
on Form 20-F, under the caption "Key Information - Risk Factors"
filed with the relevant Canadian securities regulatory authorities
in lieu of an annual information form and with the SEC, and other
factors discussed under the heading “Risk Factors” in the Company’s
Registration Statement on Form F-1 (File No. 333-232935) filed with
the SEC and other documents subsequently filed with or furnished to
the SEC. Known and unknown risks and uncertainties could cause our
actual results to differ materially from those in forward-looking
statements. Such risks and uncertainties include, among others, our
ability to raise capital and obtain financing to continue our
currently planned operations, our ability to regain compliance with
the continued listing requirements of the NASDAQ and continue to
list our Common Shares on the NASDAQ, our ability to continue as a
going concern is dependent, in part, on our ability to transfer
cash from Aeterna Zentaris GmbH to Aeterna Zentaris and the U.S.
subsidiary and secure additional financing, our now heavy
dependence on the success of Macrilen™ (macimorelin) and related
out-licensing arrangements and the continued availability of funds
and resources to successfully commercialize the product, including
our heavy reliance on the success of the License Agreement with
Novo, the global instability due to the global pandemic of
COVID-19, and its unknown potential effect on our planned
operations, including studies, our ability to enter into
out-licensing, development, manufacturing, marketing and
distribution agreements with other pharmaceutical companies and
keep such agreements in effect, our reliance on third parties for
the manufacturing and commercialization of Macrilen™ (macimorelin),
potential disputes with third parties, leading to delays in or
termination of the manufacturing, development, out-licensing or
commercialization of our product candidates, or resulting in
significant litigation or arbitration, uncertainties related to the
regulatory process, unforeseen global instability, including the
instability due to the global pandemic of the novel coronavirus,
our ability to efficiently commercialize or out-license Macrilen™
(macimorelin), our reliance on the success of the pediatric
clinical trial in the European Union (“E.U.”) and U.S. for
Macrilen™ (macimorelin), the degree of market acceptance of
Macrilen™ (macimorelin), our ability to obtain necessary approvals
from the relevant regulatory authorities to enable us to use the
desired brand names for our product, our ability to successfully
negotiate pricing and reimbursement in key markets in the E.U. for
Macrilen™ (macimorelin), any evaluation of potential strategic
alternatives to maximize potential future growth and shareholder
value may not result in any such alternative being pursued, and
even if pursued, may not result in the anticipated benefits, our
ability to take advantage of business opportunities in the
pharmaceutical industry, our ability to protect our intellectual
property, and the potential of liability arising from shareholder
lawsuits and general changes in economic conditions. Investors
should consult our quarterly and annual filings with the Canadian
and U.S. securities commissions for additional information on risks
and uncertainties. Given these uncertainties and risk factors,
readers are cautioned not to place undue reliance on these
forward-looking statements. We disclaim any obligation to update
any such factors or to publicly announce any revisions to any of
the forward-looking statements contained herein to reflect future
results, events or developments, unless required to do so by a
governmental authority or applicable law.
Investor Contact:
Jenene Thomas JTC Team T (US): +1 (833) 475-8247 E:
aezs@jtcir.com
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Apr 2023 to Apr 2024